FDA Advisers: Benefits of Newer Oral Contraceptives, Birth Control Patch Outweigh Risks

Like this article?

Get your free daily medical news from Physician's First Watch.

FDA Advisers: Benefits of Newer Oral Contraceptives, Birth Control Patch Outweigh Risks

FDA advisers concluded last week that the benefits of newer, drospirenone-containing oral contraceptives (marketed as Yaz, among others) and the contraceptive patch (Ortho Evra) still outweigh their risks for venous thromboembolism, Reuters reports.

The advisers recommended, however, that the products' labels be simplified to better explain the higher VTE risk they pose compared with older oral contraceptives.

LINK(S):

Reuters story on OCs containing drospirenone (Free)

Reuters story on birth control patch (Free)

Physician's First Watch recent coverage of drospirenone OCs and VTE (Free)

Physician's First Watch 2008 coverage of Ortho Evra and VTE (Free)

Published in Physician's First Watch December 12, 2011

Reader Remarks:

Review and add to remarks on this article

VTE risk
matthew weitzel, community health center, 11 Apr 2012 12:53 PM EST
Specialty: Family Medicine
The FDA's remark that the risk of VTE in or after pregnancy is higher than the risk of VTE on... [more]

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

The editors of Journal Watch may respond to Reader Remarks, but we cannot promise to respond to a particular remark.

Remark subject:*

Your remark:*

Fields marked with an * are required.

Name as you'd like it to appear:
First & middle initial:*

Last:*

Email address (will not
be published):*

Professional specialty:*

Place of work (optional):

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

No competing interests

Or, the following competing interests (for example, financial stakes or professional relationships):

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Article Tools

Reader Remarks

(more...)

Sign-In

Forgot your password? Login via Athens
or your institution

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!